A Multi-Center, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension.
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Sacubitril (Primary) ; Sacubitril/valsartan (Primary) ; Valsartan
- Indications Essential hypertension; Hypertension
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 04 Jul 2012 Planned patient number is 1560 as reported by European Clinical Trials Database record.
- 16 Mar 2010 Results presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC-2010).
- 16 Mar 2010 Results published in the Lancet.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History